Effect of Acupressure on Anxiety, Embarrassment, and Procedural Fear in Patients Undergoing Urodynamic Testing: Randomized Controlled Study.

Neurourol UrodynJun 3, 2026 (epub)
Clinical ResearchUrologyOpen access

Gamze Bozkul, Elife Kettas Dolek, Gülay Altun Ugras et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the impact of acupressure on anxiety, embarrassment, and procedural fear in 68 patients undergoing urodynamic testing. Results indicated that patients receiving acupressure experienced significantly lower levels of anxiety (p < 0.001), embarrassment (p < 0.001), and procedural fear (p < 0.001) immediately after the intervention and after the procedure compared to the control group.

Key findings

  • Anxiety levels decreased significantly in the acupressure group at UT2 (p < 0.001).
  • Embarrassment levels were significantly lower in the acupressure group at UT2 (p < 0.001).
  • Procedural fear was significantly reduced in the acupressure group at UT2 (p < 0.001) and UT3 (p = 0.027).
  • The control group only showed significant decreases in anxiety, embarrassment, and procedural fear at UT3.

Why it matters

Understanding methods to alleviate anxiety and fear in patients undergoing urodynamic testing can enhance patient comfort and compliance. Acupressure may serve as a valuable adjunctive therapy in clinical practice.

Source

PubMed · PMID 42233437Free full text on PubMed Central

Published in Neurourol Urodyn. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Urology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.